Checkpoint Therapeutics, Inc. Balance Sheet

Ask AI

Financial Statements

In millions of USD, except per-share amounts

	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020
ASSETS
Current Assets:
Cash and cash equivalents
Prepaid expenses and other current assets
Other receivables - related party
Total current assets
Total Assets
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities:
Accounts payable and accrued expenses
Accounts payable and accrued expenses - related party
Common stock warrant liabilities
Total current liabilities
Total Liabilities
Stockholders' Equity (Deficit)
Common Stock Value
Class A Common Shares
Common No Class
Total common Stock Value
Common stock issuable, 0 and 2,386,808 shares as of March 31, 2025 and December 31, 2024, respectively
Additional paid-in capital
Accumulated deficit
Class A Common Shares
Total Stockholders' Equity (Deficit)

Total Liabilities and Stockholders' Equity (Deficit)

Comments